avelumab

Ligand id: 8735

Name: avelumab

References
1. Nastri HG, Iffland C, Leger O, An Q, Cartwright M, Mckenna SD, Sood VD, Hao G. (2013)
Anti-pd-l1 antibodies and uses thereof.
Patent number: WO2013079174 A1. Assignee: Merck Patent Gmbh. Priority date: 28/11/2011. Publication date: 06/06/2013.
2. Pardoll DM. (2012)
The blockade of immune checkpoints in cancer immunotherapy.
Nat. Rev. Cancer12 (4): 252-64. [PMID:22437870]
3. Topalian SL, Drake CG, Pardoll DM. (2015)
Immune checkpoint blockade: a common denominator approach to cancer therapy.
Cancer Cell27 (4): 450-61. [PMID:25858804]